Skip to main content
SpringerLink
Log in

The consequences of H2 receptor antagonist — piroxicam coadministration in patients with joint disorders

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine.

Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L−1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period).

A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation.

No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anod G, Jellheden B, Sodergren J (1983) Toleration of piroxicam. Int Med 3: 37–41

    Google Scholar 

  • Bartle WR, Walker E, Shapero T (1982) Effect of cimetidine on phenytoin metabolism. Clin Pharmacol Ther 31: 202

    Google Scholar 

  • Brune K (1985) Clinical relevance of nonsteroidal anti-inflammatory drug pharmacokinetics. Eur J Rheumatol 8: 18–23

    Google Scholar 

  • Begg EJ, Williams KM, Wade DN, O'Shea KF (1983) No significant effect of cimetidine on the pharmacokinetics of misonidazole in man (letter). Br J Clin Pharmacol 15: 575–576

    Google Scholar 

  • Collier DStJ, Pain JA (1985) Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 26: 359–363

    Google Scholar 

  • Conrad KA, Mayersohn M, Bliss M (1984) Cimetidine does not alter ibuprofen kinetics after a single dose. Br J Clin Pharmacol 18: 624–626

    Google Scholar 

  • Darragh A, Gordon AJ, O'Byrne H, Hobbs D, Casey E (1985) Single and steady-state pharmakokinetics of piroxicam in elderly vs young adults. Eur J Clin Pharmacol 28: 305–309

    Google Scholar 

  • Dey NG, Castlden CM, Ward J, Cornhill J, McBurney A (1983) The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol 16: 438–440

    Google Scholar 

  • Farnham DJ (1982) Studies of isoxiam in combination with aspirin, warfarin sodium and cimetidine. Semin Arthritis Rheum 12 [Suppl 2]: 179–183

    Google Scholar 

  • Grygiel JJ, Miners JO, Drew R, Birkett DJ (1984) Differential effects of cimetidine on theophylline metabolic pathways. Eur J Pharmacol 26: 335–340

    Google Scholar 

  • Hetzel D, Birkett D, Miners J (1979) Cimetidine interaction with warfarin. Lancet II: 639

    Google Scholar 

  • Hobbs DC, Twomey TM (1979) Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J Clin Pharmacol 19: 270–281

    Google Scholar 

  • Hobbs DC, Gordon AJ (1984) Absence of an effect of age on the pharmacokinetics of piroxicam. In: Richardson R. G. (ed) The rheumatological disease process: focus on piroxicam. The Royal Society Of Medicine, London pp 91–94

    Google Scholar 

  • Holford NHG, Altman D, Riegelman S, Buskin JN, Upton RA (1981) Pharmacokinetic and pharmacodynamic study of cimetidine administered with naproxen (abstract). Clin Pharmacol Ther 29: 251–252

    Google Scholar 

  • Ishizaki T, Nomura T, Abe T (1979) Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm 7: 369–381

    Google Scholar 

  • Klein A, Sami M, Selinger K (1985) Mexiletine kinetics in healthy subjects taking cimetidine. Clin Pharmacol Ther 37: 669–673

    Google Scholar 

  • Klotz U, Arvela P, Pasanen M, Kroemer H, Pelkonen O (1987) Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmacol Ther 33: 157–161

    Google Scholar 

  • Knodell RG, Holtzman JL, Crankshaw DL, Steele NM, Stanley LA (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2 receptor antagonists. Gastroenterology 82: 84–88

    Google Scholar 

  • Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP (1991) Differential inhibition of individual liver cytochromes P-450 by cimetidine. Gastroenterology 101: 1680–1691

    Google Scholar 

  • Langman MJS (1989) Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 96: 640–646

    Google Scholar 

  • Leemann T, Transon C, Dayer P (1992) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 29–34

    Google Scholar 

  • Lu AYH (1979) Multiplicity of liver drug metabolism enzymes. Drug Metab Rev 10: 187–208

    Google Scholar 

  • Milligan PA (1992) Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by HPLC. J Chromatogr Biomed Appl 576: 121–128

    Google Scholar 

  • Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg Jr KV (1980) Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology 79: 912–916

    Google Scholar 

  • Pitts NE (1982) Efficacy and safety of piroxicam. Am J Med 72: 77–87

    Google Scholar 

  • Reilly PEB, Carrington LE, Windsor DJ (1983) The interaction of cimetidine with rat liver microsomes. Biochem Pharmacol 32: 831–835

    Google Scholar 

  • Roberts RK, Grice J, Wood L, Petroff V, McGuffie C (1981) Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology 81: 19

    Google Scholar 

  • Rogers HJ, Spector RG, Morrison PJ, Bradbrook ID (1981) Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects. Eur J Rheumatol 4: 303–308

    Google Scholar 

  • Rugstad HE, Hundal O, Holme I, Herland OB, Husby G, Giercksky K-E (1986) Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin Rheumatol 5: 389–398

    Google Scholar 

  • Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12: 321–366

    Google Scholar 

  • Verbeeck RK, Richardson CJ, Blocka KLN (1986) Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789–796

    Google Scholar 

  • Woolf AD, Rogers HJ, Bradbrook ID, Corless D (1983) Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients. Br J Clin Pharmacol 16: 433–437

    Google Scholar 

  • Zhao J, Leemann T, Dayer P (1992) In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 51: 575–581

    Google Scholar 

Download references

Author information

Author notes

  1. P. A. Milligan

    Present address: Syntex Research Scotland, Research Park, Heriot-Watt University, Edinburgh, UK

Authors and Affiliations

  1. Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK

    P. A. Milligan, A. W. Kelman & B. Whiting

  2. Department of Rheumatology, Stobhill General Hospital, Glasgow, UK

    P. E. McGill

  3. School of Medicine, University of South Carolina, Columbia, USA

    C. W. Howden

Authors
  1. P. A. Milligan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. E. McGill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. W. Howden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. W. Kelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Whiting
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milligan, P.A., McGill, P.E., Howden, C.W. et al. The consequences of H2 receptor antagonist — piroxicam coadministration in patients with joint disorders. Eur J Clin Pharmacol 45, 507–512 (1993). https://doi.org/10.1007/BF00315306

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315306

Key words

Search

Navigation